Pharma Report Profile
Gilead's current and future success lies in the hands of its antiviral franchise.
J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.
Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.
There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.
Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.
AstraZeneca has embarked on what's likely to be a long, rough ride.
Analysts agree that Teva is casting a healthy financial shadow.
As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.
On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.
The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.
Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.
Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.
Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.
Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.
The year 2015 was one of restructuring for GlaxoSmithKline.
In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.
After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.
Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.
So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.
Immuno-oncology was the story at Bristol-Myers Squibb in 2015.
- Publicis Health formalizes new name, promotes 3 execs
- Five things for pharma marketers to know: Monday, February 27, 2017
- Deloitte taps Havas Lynx's Mickelberg as MD
- Five things for pharma marketers to know: Wednesday, February 22, 2017
- Five things for pharma marketers to know: Thursday, February 23, 2017